Executive brief
Virtual CISO (vCISO) for Life Sciences gives emerging biotech and biopharma companies access to strategic cybersecurity leadership without the cost and delay of building a full internal executive security function. For organizations managing intellectual property, clinical data, cloud platforms, and regulated operations, that kind of leadership is becoming essential.
Life sciences companies operate in a high-stakes environment where cybersecurity is tied directly to business continuity, investor confidence, regulatory readiness, and long-term growth. Protecting sensitive data is not just an IT concern. It is a core business requirement.
Emerging biotech firms face a distinct risk profile. They are often moving quickly, adopting new technologies, collaborating across external networks, and operating with lean internal teams. That combination can create serious exposure if cybersecurity strategy does not keep pace.
Intellectual property theft targeting proprietary drug development and clinical trial data
Ransomware attacks that disrupt access to critical research and operational systems
Regulatory compliance risks tied to frameworks such as 21 CFR Part 11, GDPR, and HIPAA
Third-party and supply chain vulnerabilities introduced through CROs, manufacturers, and cloud providers